Searched for
SACUBITRIL
In major move, patent of Novartis' blockbuster cardiac drug revoked by IndiaThe Indian Patent Office revoked Novartis' patent for Vymada, a heart failure drug, citing a lack of novelty and inventive step. This decis...- Heart of the matter: Sales of cardiac drugs beat strongerHeart disease is increasing in India. This is boosting sales of cardiac drugs. Sales have risen nearly 50% in five years. Younger people ar...
- Q3 results today: Power Grid, Divi's Labs among 104 companies to announce earnings on MondayEarnings results for several companies, including Power Grid, Divi's Labs, and Tata Chemicals, will be released soon. Power Grid is expecte...
- Stocks in news: NBCC, Biocon, Maruti Suzuki, Tata Motors, Bajaj Finance, FirstCry, UnicommerceThe Board of NBCC approved a bonus issue of shares to shareholders in the ratio of 1:2, which means investors will get one additional share...
- Biocon unit gets USFDA nod for generic drugBiocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, f...
- Zydus Lifesciences gets USFDA nod to market chronic heart failure treatment drugZydus Lifesciences Ltd has received final approval from the USFDA to market its generic Sacubitril and Valsartan tablets for treating chron...
- Alkem Labs to grow chronic therapies, biosimilars to drive future growth: MDAlkem Laboratories, a top-seller of antibiotics, is focusing on the chronic therapy segments and is investing heavily in biosimilars and co...
- Alkem Labs to grow chronic therapies to drive future growth: MDThe Mumbai-based drug maker, which entered the US generics market over a decade ago, is also scaling back its investments in oral solids in...
- Why Mankind has an edge over its peers? Rajeev Juneja explainsIn 95, our turnover was Rs 5 crore and every year, the thought was, whatever we are doing in one year, can we do in one month? On this phil...
- Novartis heart drug price may fall by 60% on generic rollouts"At least 30-40 generic brands are expected to hit the market next in a couple of weeks," said Hari Natarajan, managing director, Pronto Co...
- Dr Reddy's cuts price of cardiovascular drug Cidmus"Following the price reduction, Cidmus will be priced at Rs 29 for 50 mg (down from Rs 78.32); Rs 49 for 100 mg (down from Rs 83.86); Rs 79...
- Natco Plea: Delhi high court sets aside Novartis patentNatco filed writ petition citing procedural irregularities and violation of principles of natural justice by the Assistant Controller of Pa...
- HC reserves order on Natco's plea over patent for Novartis drugNatco has argued before Justice C Hari Shankar against the grant of patent by IPO to the pharmaceutical composition comprising combination ...
- JB Pharma cuts price of its top-selling heart failure drug Azmarda by 50%After the price reduction, Azmarda 50 mg will be available at Rs 39.6 per tablet as compared to Rs 78 per tablet. Azmarda is one of the top...
- Dr Reddy's buys Novartis cardiovascular brand Cidmus in India for Rs 456 croreDr. Reddy’s will look to leverage its wide base to engage with healthcare professionals, and to significantly enhance the reach of the prod...
- Delhi HC restrains generic pharma firms from making, selling patent drug of NovartisThe plea said the plaintiff through a press release of January 28, 2019 issued by the defendant came to know about its act in launching a p...
- Natco dares Novartis with new heart drugAccording to data from AIOCD PharmaTrac, an agency that closely tracks pharmaceutical sales, Vymada had sales of Rs 68.3 crore for December...
- Stocks in the news: DHFL, ICICI Bank, Bajaj Auto, NTPC, BoB, Axis and YES BankHere are a few stocks, which may buzz the most in today's trade.
- Novartis gets USFDA nod for heart failure drugThe Swiss drug major said the USFDA's decision was based on results of a study on 8,442 patients, including 637 from India.
Load More
